After discontinuing intramuscular testosterone, my prostate-specific antigen (PSA) returned to the normal range and my urologist is comfortable with fractionated PSA results; I am now symptomatic. Should I restart testosterone therapy?

Yes, restart testosterone therapy with close PSA monitoring

Given that your PSA normalized after stopping testosterone, your urologist is comfortable with the fractionated PSA results, and you are now symptomatic from hypogonadism, you should restart testosterone therapy under careful urological surveillance. This approach aligns with established guidelines for managing hypogonadal men with prior PSA elevations 1, 2.

Clinical Reasoning

The key facts supporting testosterone resumption are:

• PSA returned to normal range after testosterone discontinuation, suggesting the prior elevation was testosterone-induced rather than malignancy-related
• Fractionated PSA is reassuring to your urologist (likely showing benign pattern)
• You are symptomatic from hypogonadism, which significantly impacts quality of life
• No evidence of prostate cancer was detected during the evaluation

This scenario represents a common clinical situation where testosterone transiently increases PSA through its physiological effects on prostate tissue, not through unmasking occult cancer 3, 4.

Monitoring Protocol Upon Restart

The Endocrine Society guidelines provide explicit monitoring parameters 1:

Initial Phase (First 6 months):

• Check PSA at 3 months after restarting
• Monitor testosterone levels to achieve mid-normal range
• Check hematocrit at 3 months

Ongoing Surveillance:

• PSA every 3-6 months for the first year
• Then annually if stable
• Annual hematocrit monitoring

Critical PSA Thresholds for Urological Referral

You need urological consultation if any of the following occur 1, 2, 5:

• PSA increase >1.4 ng/mL within any 12-month period (most important threshold)
• PSA velocity >0.4 ng/mL per year (using 6-month value as reference)
• Absolute PSA >4.0 ng/mL
• Any prostatic abnormality on digital rectal examination
• Prostate symptoms score (AUA/IPSS) >19

Expected PSA Response

Research shows that testosterone therapy typically increases PSA by a mean of 0.3-0.44 ng/mL in hypogonadal men 6. In severely hypogonadal men, the median increase is approximately 0.70 ng/mL 3. These are physiological responses, not indicators of malignancy.

Important distinction: The Endocrine Society uses a PSA increase threshold of >1.4 ng/mL because this represents the 90% confidence limit for normal PSA variability in men with benign prostatic hyperplasia 6. Increases below this threshold are generally considered within expected variation.

Common Pitfalls to Avoid

1. Don't panic at small PSA increases - Rises <1.4 ng/mL over 12 months are typically benign and testosterone-related 6

2. Confirm PSA elevations - Transient elevations can occur from prostatitis, benign prostatic hyperplasia, or test variability 6. Always repeat before making decisions.

3. Don't use overly aggressive PSA thresholds - Some older literature suggests biopsy for any PSA increase >1.0 ng/mL 5, but current Endocrine Society guidelines use the more evidence-based threshold of >1.4 ng/mL 1

4. Monitor hematocrit - If hematocrit exceeds 54%, stop therapy temporarily, evaluate for sleep apnea/hypoxia, then restart at reduced dose 1

Formulation Considerations

When restarting, aim for mid-normal testosterone range (not supraphysiological levels) 1. The specific formulation matters for monitoring timing:

• Injectable testosterone (enanthate/cypionate): Check levels midway between injections
• Transdermal gels: Check anytime after 1 week on treatment
• Patches: Check 3-12 hours after application

Evidence Quality Note

The recommendation to restart testosterone in your situation is based on Grade 2 evidence from Endocrine Society guidelines 1, 2, meaning there is moderate certainty about the risk-benefit ratio. The monitoring protocols are strongly recommended (Grade 1) to detect the small subset of men who may develop prostate issues during therapy 1.

Recent research confirms that PSA levels remain stable in most men on long-term testosterone therapy, with prostate cancer incidence no higher than the general population 4, 7. In the subset who develop PSA increases, stopping testosterone typically results in PSA decline without additional intervention 8.

Your situation—with PSA normalization off testosterone and urologist approval—represents an ideal scenario for cautious testosterone resumption with appropriate surveillance.